Financial Data and Key Metrics Changes - Total operating revenue for the full year 2025 was $430.4 million, an increase of 10.7% compared to 2024 [11] - Operating revenue for the fourth quarter of 2025 was $105.4 million, an increase of 11.5% over the fourth quarter of 2024 [11] - Adjusted EBITDA for the full year 2025 was $40.2 million, essentially unchanged from 2024, while fourth quarter adjusted EBITDA was $9.2 million, an increase of 32% year-over-year [11][12] - The adjusted operating ratio for the fourth quarter improved modestly compared to the prior year despite challenges [6][11] Business Line Data and Key Metrics Changes - The company delivered over 2.3 million vehicles in 2025, representing a 16.2% increase from 2024, although revenue per unit decreased by about 6% [5][12] - The fourth quarter revenue and unit volumes each increased over 11% year-over-year, driven by the Brothers' acquisition and new business wins [6] Market Data and Key Metrics Changes - The automotive market peaked in March and April 2025, but the remainder of the year was weaker than expected, with a lower year-over-year seasonal volume push in the fourth quarter [5][6] - January 2026 saw lower-than-forecasted SAR, potentially the lowest monthly SAR in several years due to severe winter weather impacting dealership operations [8] Company Strategy and Development Direction - The company aims for continued margin expansion and market share gains, focusing on sustainable profitability and reinvestment [9][10] - The forecast for SAR in 2026 is lower than 2025 actual, with growth expected to come from internal initiatives rather than market conditions [13] - The company is prioritizing profitability over top-line growth, making disciplined choices regarding business retention and new contracts [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying resiliency of the automotive market, supported by replacement demand and lower interest rates [9] - The company anticipates improved consumer demand in the coming months as weather impacts ease and sales incentives remain strong [8] - Management noted that while the market environment was challenging in 2025, they are optimistic about potential improvements in the second half of 2026 [70] Other Important Information - A non-cash goodwill impairment charge of $27.8 million was recorded during the quarter, reflecting changes in market conditions [8] - The company’s net debt to trailing 12-month adjusted EBITDA improved from 2.2x to 1.5x, enhancing flexibility for future capital structure decisions [12] Q&A Session Summary Question: Expectations for Q1 revenue and operating ratio - Management expects sequential revenue to be down but modest improvement in operating ratio [21] Question: Impact of tightening capacity in the auto hauling market - Management noted that non-domiciled CDL issues are impacting driver recruitment but the company is somewhat insulated due to its hiring practices [23] Question: Revenue per unit expectations for 2026 - Management anticipates stability in revenue per unit, with no significant increases expected [28] Question: Capital allocation priorities - The company will prioritize debt paydown but remains open to M&A opportunities [30] Question: Updates on revenue mix and competitive pricing - Management indicated that a healthier demand environment is needed for spot market recovery, and they are maintaining discipline in pricing [35][39] Question: Updates on contract awards and market share gains - Management reported some new contract awards but also noted losses due to pricing dynamics [48] Question: M&A pipeline and expectations for 2026 - The company is actively engaged in developing a pipeline and expects to make 1-2 acquisitions in 2026 [53]

Core Insights - Ralliant Corporation reported operational resilience with sequential revenue growth for three consecutive quarters, despite a significant non-cash accounting charge impacting GAAP results [1][5] Financial Performance - Q4 2025 revenue reached $554.6 million, a 1% increase year-over-year from $548.1 million, and showed sequential growth [6] - Adjusted net earnings were $78.5 million, with adjusted diluted EPS of $0.69, surpassing consensus estimates of approximately $0.67 [6] - GAAP net loss was $(1,373.9) million, or $(12.10) per diluted share, primarily due to a $1.4 billion non-cash goodwill impairment charge in the Test & Measurement segment [2][6] - Operating cash flow was $101.6 million, and free cash flow was $91.6 million [6] Market Reaction - On February 5, 2026, Ralliant's stock closed at $38.39, down approximately 31.79% from the previous close of $56.28, reflecting market concerns over the impairment and future EV growth prospects [4] Guidance and Analyst Outlook - For Q1 2026, Ralliant expects revenue between $508 million and $522 million, representing 5-8% year-over-year growth [7] - Full-year 2026 guidance includes revenue of $2.1 to $2.2 billion, adjusted EBITDA margin of 18-20%, and adjusted EPS of $2.22 to $2.42 [7] - Analysts maintain a consensus "Moderate Buy" to "Buy" rating, with price targets in the mid-$50s to low-$60s range, indicating potential upside despite near-term challenges [4][5]

This story was originally published on CFO Dive. To receive daily news and insights, subscribe to our free daily CFO Dive newsletter. Nearly four years after dropping a years-long project that would have changed goodwill accounting, the Financial Accounting Standards Board is revisiting the matter.  The challenges related to improving generally accepted accounting standards for the contentious topic of goodwill were raised again by stakeholders in discussions that grew out of the U.S. accounting standard s ...

Core Viewpoint - CVS experienced a significant stock drop of 14% following a disappointing 0.09% rate increase announcement for 2027 by CMS, which fell short of investor expectations of 4-6% [2][3] Financial Performance - CVS's revenue for 2025 is projected to exceed $400 billion, with adjusted operating income estimated between $14.22 billion and $14.39 billion [12] - The company reported an adjusted EPS of $1.60 for Q3 2025, surpassing estimates of $1.36 [11] - Aetna's medical loss ratio improved to 87.3% from 90.4% in Q3 2024, indicating stabilization in their insurance business [11][6] Business Segments - Approximately 33% of CVS's revenue comes from premiums, making it less vulnerable to Medicare Advantage challenges compared to competitors like Humana [3] - CVS operates a diversified business model, including retail pharmacies (9,000 locations), Pharmacy Benefit Management (CVS Caremark with 87 million members), and Aetna [2] Strategic Challenges - CVS recorded a $5.7 billion goodwill impairment charge in Q3 2025 related to its acquisition of Oak Street Health, indicating difficulties in executing its healthcare delivery strategy [6][9] - The company is terminating 16 Oak Street clinics and adjusting its growth strategy due to the underperformance of this acquisition [9] Market Outlook - CVS's guidance indicates expectations for margin improvement despite stable revenue, suggesting operational efficiency gains alongside Aetna's stabilization [7] - The 2027 Medicare rate proposal is expected to pressure Aetna's margins, raising concerns about the impact on CVS's overall performance [8] Valuation Metrics - CVS's current stock price is $72, with a forward P/E ratio of 10.2x, which is considered inexpensive compared to its historical trading range of 12-15x [13][14] - The company is projected to generate robust operating cash flow of $7.5 billion to $8.0 billion in 2025, with a quarterly dividend of $0.665 per share, yielding 3.3% [15] Investment Perspective - CVS offers a higher level of diversification compared to competitors like UnitedHealth and Humana, making it a more balanced investment option despite the complexities involved [16][17] - The stock's current valuation reflects ongoing challenges but does not indicate a catastrophic outlook, making it an attractive option for investors seeking exposure to the healthcare sector with less regulatory risk [17]

Company Overview - CVS Health Corporation has a market cap of $105.4 billion and provides integrated health solutions through its Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments, offering health insurance, pharmacy benefit management, and retail pharmacy services nationwide [1] Stock Performance - CVS stock has significantly outperformed the broader market over the past 52 weeks, surging 53.8% compared to the S&P 500 Index's gain of 13.9% [2] - Year-to-date, CVS stock has risen 5.7%, while the S&P 500 Index has only gained 1.5% [2] - CVS shares have also outpaced the State Street Health Care Select Sector SPDR ETF's return of 9.6% over the past 52 weeks [3] Recent Financial Results - On October 29, CVS reported a Q3 2025 loss of $3.13 per share, primarily due to a $5.7 billion goodwill impairment charge related to its Health Care Delivery unit, resulting in a $3.2 billion operating loss compared to a profit the previous year [4] - The company has sharply cut its full-year 2025 EPS guidance to a loss of $(0.34) - $(0.24) from prior expectations of $3.84 - $3.94 [4] Future Earnings Expectations - For the fiscal year ending December 2025, analysts expect CVS' adjusted EPS to grow 22.7% year-over-year to $6.65, with a promising earnings surprise history [5] - Among 24 analysts covering the stock, the consensus rating is a "Strong Buy," based on 19 "Strong Buy" ratings, two "Moderate Buys," and three "Holds" [5] Analyst Ratings and Price Targets - The current analyst configuration is slightly less bullish than three months ago, with 20 "Strong Buy" ratings [6] - Bernstein raised its price target on CVS Health to $91 while maintaining a "Market Perform" rating, with a mean price target of $94.74, suggesting a nearly 13% premium to CVS' current price [6] - The highest price target of $105 indicates a potential upside of 25.2% [6]

Core Viewpoint - West Fraser Timber Co. Ltd. will record a non-cash impairment of approximately $409 million in its Lumber segment goodwill for Q4-2025 due to ongoing challenging economic conditions [2] Financial Performance - The impairment reflects a recalibration of assumptions in the annual goodwill impairment test, influenced by species-specific product pricing trends, lower demand for wood chip residuals, and the anticipated depth and duration of the current downcycle [2] - The impairment represents the entire amount of goodwill associated with the Company's U.S. lumber operations [2] Operational Guidance for 2026 - SPF shipments are targeted to be between 2.4 to 2.7 billion board feet [6] - SYP shipments are also targeted to be between 2.4 to 2.7 billion board feet [6] - N.A. OSB shipments are expected to be between 5.9 to 6.3 billion square feet (3/8-inch basis) [6] - European and U.K. OSB shipments are projected to be between 1.0 to 1.25 billion square feet (3/8-inch basis) [6] - Input costs, including resins and chemicals, are expected to remain stable, while contractor availability and capital equipment lead times are anticipated to improve [6] - Capital expenditures are expected to be in the range of $300 to $350 million [6] Company Overview - West Fraser is a diversified wood products company with over 50 facilities across Canada, the U.S., the U.K., and Europe, focusing on sustainable forest practices [4] - The Company produces a variety of products including lumber, engineered wood products, pulp, newsprint, and wood chips, which are utilized in home construction, industrial applications, and paper products [4]

Core Insights - Long Cast Advisers reported a cumulative net return improvement of 4% in Q3 2025, with a total cumulative return of 266% net of fees since inception in November 2015, translating to a 14% CAGR [1] Company Overview: Quest Resource Holding Corporation (NASDAQ:QRHC) - Quest Resource Holding Corporation provides waste and recycling services and is headquartered in The Colony, Texas [2] - The stock experienced a one-month return of 29.66%, but has lost 73.82% of its value over the past 52 weeks, closing at $1.88 per share with a market capitalization of $39.236 million on November 27, 2025 [2] Performance Analysis - Year-to-date, Quest Resource Holding Corporation has been a significant detractor for Long Cast Advisers' portfolio, leading to its removal from the top-five holdings [3] - The company reported revenue of $63.3 million in Q3 2025, which is a 13% decrease compared to Q3 2024 but a 6.4% increase from Q2 2025 [4] Management and Valuation Concerns - The company has improved management and operational processes, making it a more reasonable investment despite its past performance [3] - There is a notable discrepancy between $80 million in goodwill and a $35 million market capitalization, which is expected to trigger an annual impairment test [3] Hedge Fund Interest - Quest Resource Holding Corporation is not among the 30 most popular stocks among hedge funds, with only 8 hedge fund portfolios holding the stock at the end of Q3 2025, down from 12 in the previous quarter [4]

Core Viewpoint - LFTD Partners Inc. reported its financial results for Q3 2025, showing significant improvements in revenue and net income, but faces potential severe impacts from new federal legislation banning intoxicating hemp-derived products effective November 12, 2026 [1][4]. Financial Results - Revenue increased by 4% to $9,056,742, up from $8,691,675 [5]. - Operating income was $1,312,791, a turnaround from an operating loss of $140,703 [5]. - Net income reached $634,257, compared to a net loss of $194,399 [5]. - Basic and diluted net income per share improved to $0.04, up from a loss of $0.01 per share [5]. - Cash on hand decreased by 7% to $2,920,664, down from $3,146,947 [5]. - Inventory increased by 8% to $10,077,375, up from $9,316,291 [5]. - Current assets decreased by 14% to $14,591,256, down from $16,928,005 [5]. - Current ratio improved to 3.02 from 2.78 [5]. - Working capital decreased by 10% to $9,764,165, down from $10,843,994 [5]. - Notes payable to Surety Bank decreased by 30% to $2,336,259, down from $3,348,790 [5]. Legislative Impact - The new federal legislation could eliminate approximately half or more of Lifted's sales, as hemp-derived products accounted for about 47% of sales during Q3 2025 [6]. - The Act may necessitate goodwill impairment charges, potentially affecting half or more of the recognized goodwill totaling $23,092,794 [6]. - An investment impairment charge may be required for LFTD Partners' investment in Ablis, which was reported as $399,200 as of September 30, 2025 [6]. - Significant inventory write-offs are anticipated due to potential negative impacts on pricing and availability of hemp-derived products [6]. Company Overview - LFTD Partners Inc. is the parent corporation of Lifted Made, which manufactures and sells hemp-derived and other psychoactive products under various brands [7]. - The company also holds a 4.99% stake in Ablis and a craft distillery, Bendistillery Inc. [7].

Core Viewpoint - PetMed Express, Inc. has announced preliminary second quarter fiscal year 2026 results, indicating a significant decline in net sales compared to the previous year, and has filed a Notification of Late Filing with the SEC due to delays in filing its Form 10-Q [1][2]. Financial Performance - For the fiscal second quarter ended September 30, 2025, net sales are estimated to range from $43.4 million to $44.5 million, a decrease from $58.0 million in the prior year period [2]. - For the six months ended September 30, 2025, net sales are estimated to range from $94.5 million to $95.6 million, down from $124.3 million in the prior year period [2]. - The company reported $36.1 million in cash and no debt as of September 30, 2025 [4]. Compliance and Regulatory Issues - On November 12, 2025, the company received a notice from Nasdaq indicating non-compliance due to delays in filing its Quarterly Reports for the periods ended June 30, 2025, and September 30, 2025 [5]. - The company must submit an update to its original plan to regain compliance by November 28, 2025, following a previous submission on September 2, 2025 [6]. - The notice does not have an immediate effect on the listing of the company's common stock on Nasdaq [6]. Operational Challenges - The company is currently unable to provide estimates for operating income or net income for the three- and six-month periods ended September 30, 2025, due to ongoing analysis of a potential goodwill impairment charge [3]. - The company is working diligently to complete and file its Q1 10-Q and Q2 10-Q as soon as possible to regain compliance with Nasdaq listing standards [7]. Company Overview - PetMed Express, Inc. is a pioneer in the direct-to-consumer pet healthcare sector, offering a range of pet health solutions through its brands, including PetCareRx [8]. - The company is licensed across all 50 states and focuses on providing value, convenience, and care to pet owners [8].

Core Insights - The company reported solid financial results for Q3 2025, generating $2.7 billion in revenue and $638 million in adjusted EBITDA, with an adjusted EBITDA margin of 24% despite challenging market conditions [5][20][21] - The roofing segment faced a uniquely quiet storm season, impacting demand, while the insulation business experienced weakening residential trends [6][7][10] - The company remains focused on disciplined capital allocation, returning over $700 million to shareholders and maintaining a commitment to return $2 billion over 2025 and 2026 [6][23] Financial Performance - Revenue for Q3 decreased by 3% year-over-year due to lower volumes, but adjusted EBITDA remained strong at $638 million [20][21] - The company achieved an adjusted earnings per diluted share of $3.67 for the quarter [21] - Free cash flow for Q3 was $752 million, up from $558 million in the same period last year, reflecting disciplined working capital management [22] Market Conditions - The roofing market was impacted by the absence of named storms in the U.S. for the first time in a decade, leading to lower demand [7][25] - The insulation business saw a 7% revenue decline primarily due to lower demand for residential products and the sale of the building materials business in China [27] - The doors segment experienced a 5% revenue decline, attributed to slower discretionary spending and weaker new construction activity [29] Strategic Initiatives - The company is investing in operational efficiencies and expanding capacity, including a new plant in Alabama for roofing products [12][14] - The contractor network has grown by about 9% since the beginning of the year, reflecting the company's strong commercial position [13] - The company is on track to achieve $125 million in enterprise cost synergies from the doors business integration [30][15] Outlook - For Q4, the company anticipates revenue to decline mid to high teens compared to the prior year, with adjusted EBITDA margins expected to be around 16% to 18% [34][40] - The roofing segment is expected to see a high 20% decline in shipments due to lower storm activity and inventory management [35] - The insulation business is projected to decline high single digits in revenue, primarily due to lower demand in North America [38]